

W. H. O. Terminology Report

DRS. ALLEN, AMOS, BATCHELOR, BODMER,
CEPPELLINI, DAUSSET, KISSMEYER-NIELSEN, MORRIS, PAYNE,
VAN ROOD & WALFORD

Secretary, on behalf of W. H. O., Dr. Trnka

The HL-A terminology committee discussed the recognition of previously designated specificities. It was felt that antigens HL-A2, 8, and 9 were readily recognizable as shown by the coincidence of reactions of several sera submitted by different investigators but that the lack of good correlation between some sera submitted to the Workshop as defining HL-A1, 3, 5, and 7 merited comment. By majority decision it was agreed to recommend that these specificities be defined as being recognized by sera giving the lowest frequency of strong positive reactions against two or more cell panels (see report of Workshop).

Four new specificities designated HL-A10, 11, 12, and 13 were agreed upon as having been recognized by two or more sera during the Workshop. Table I lists the four new HL-A specificities and some of the previous designations given to them.

Six other specificities were discussed as possibly meriting formal designation. However, since these specificities were recognized by only one serum it was felt prudent to defer action until support was given through

the availability of other sera recognizing the same specificities.

A new procedure for recognizing possible new specificities was agreed upon. Two ml of serum thought to be type specific and previously shown to be monospecific should be sent to each of the W. H. O. labs listed above. This procedure would insure rapid recognition of the new specificity in representative panels and would give optimal probability of matching the new with pre-existing, but previously non-designated, specificities. New designations will only be assigned periodically at the time of a meeting of the committee members.

New designations	Representative equivalents
HL-A10	Da17, To13, Te12
HL-A11	KN-ILN*, Te13, Da21, To26
HL-A12	Da4, KN-T12, Ao15, To11, Te9
HL-A13	KN-HN, To21, Bt23